Abstract
850 Purpose: To evaluate the influence of early chemotherapy-induced amenorrhea (CT-IA) on disease free survival (DFS) and overall survival (OS), we studied data from premenopausal patients (pts) with receptor positive early breast cancer treated with adjuvant chemotherapy without any hormone therapy. Patients and Methods: Retrospectively, we reviewed data from 130 premenopausal pts with localized hormone-sensitive cancer. These pts were treated between 1985 and 1995. They all underwent a loco-regional treatment and adjuvant chemotherapy. Early CT-IA was defined as an amenorrhea arising during the first year following the beginning of the chemotherapy. Univariate predictors of early CIA were examined. DFS and OS analyses were performed with Kaplan Meier method and Cox models. Results: Median follow-up was 9 years. Mean age was 42.9 ± 5 years. Ninety two percent of pts had histologically proven positive axillary nodes. One third of the pts had received an anthracycline containing chemotherapy. Early CT-IA occurred during or after adjuvant chemotherapy in 57% of pts. It was definitive in 91% of pts. In both the univariate and the multivariate analyses, age was the only CT-IA predictor in our study. Women who experienced early CT-IA tended to have a better disease-free survival, but the difference was not significant, probably due to the small number of pts. OS was not different. Conclusion: Early CT-IA increases the cytotoxic effect of chemotherapy in hormone sensitive breast cancer pts. The importance of this effect on DFS and possibly on OS could be shown with studies including a higher number of pts. No significant financial relationships to disclose.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call